Cognition Therapeutics, Inc.
CGTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.71 | -0.13 | 58.71 | -0.42 |
| FCF Yield | -102.21% | -29.14% | -30.72% | -2.60% |
| EV / EBITDA | -0.11 | -1.05 | -0.98 | -7.99 |
| Quality | ||||
| ROIC | -275.84% | -197.28% | 3.55% | -48.96% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.62 | 0.87 | 0.31 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -76.17% | 13.57% | -411.32% | -6.24% |
| Safety | ||||
| Net Debt / EBITDA | 0.72 | 1.12 | 1.90 | 5.10 |
| Interest Coverage | -2,158.64 | 0.00 | -1,555.39 | -32.02 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.05 |
| Cash Conversion Cycle | -2,722.41 | -5,351.88 | -4,995.06 | -8,532.37 |